Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeanne Amiel is active.

Publication


Featured researches published by Jeanne Amiel.


Nature | 2008

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

Isabelle Janoueix-Lerosey; Delphine Lequin; Laurence Brugières; Agnès Ribeiro; Loïc de Pontual; Valérie Combaret; Virginie Raynal; Alain Puisieux; Gudrun Schleiermacher; Gaëlle Pierron; Dominique Valteau-Couanet; Thierry Frebourg; Jean Michon; Stanislas Lyonnet; Jeanne Amiel; Olivier Delattre

Neuroblastoma, a tumour derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumours in childhood. It usually occurs sporadically but familial cases are observed, with a subset of cases occurring in association with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene. Here we conducted genome-wide comparative genomic hybridization analysis on a large series of neuroblastomas. Copy number increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was observed recurrently. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Through subsequent direct sequencing of cell lines and primary tumour DNAs we identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots. Germline mutations were observed in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene. Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation. Altogether, these data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.


Nature Genetics | 2011

Germline deletion of the miR-17 ∼ 92 cluster causes skeletal and growth defects in humans

Loïc de Pontual; Evelyn Yao; Patrick Callier; Laurence Faivre; Valérie Drouin; Sandra Cariou; Arie van Haeringen; David Geneviève; Alice Goldenberg; Myriam Oufadem; Sylvie Manouvrier; Arnold Munnich; Joana A. Vidigal; Michel Vekemans; Stanislas Lyonnet; Alexandra Henrion-Caude; Andrea Ventura; Jeanne Amiel

MicroRNAs (miRNAs) are key regulators of gene expression in animals and plants. Studies in a variety of model organisms show that miRNAs modulate developmental processes. To our knowledge, the only hereditary condition known to be caused by a miRNA is a form of adult-onset non-syndromic deafness, and no miRNA mutation has yet been found to be responsible for any developmental defect in humans. Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17∼92 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities. We demonstrate that haploinsufficiency of miR-17∼92 is responsible for these developmental abnormalities by showing that mice harboring targeted deletion of the miR-17∼92 cluster phenocopy several key features of the affected humans. These findings identify a regulatory function for miR-17∼92 in growth and skeletal development and represent the first example of an miRNA gene responsible for a syndromic developmental defect in humans.


Journal of Medical Genetics | 2011

RET and GDNF mutations are rare in fetuses with renal agenesis or other severe kidney development defects

Cécile Jeanpierre; Guillaume Macé; Mélanie Parisot; Vincent Morinière; Audrey Pawtowsky; Marion Benabou; Jelena Martinovic; Jeanne Amiel; Tania Attié-Bitach; Anne-Lise Delezoide; Philippe Loget; Patricia Blanchet; Dominique Gaillard; Marie Gonzales; Wassila Carpentier; Patrick Nitschke; Frédéric Tores; Laurence Heidet; Corinne Antignac; Rémi Salomon

Background The RET/GDNF signalling pathway plays a crucial role during development of the kidneys and the enteric nervous system. In humans, RET activating mutations cause multiple endocrine neoplasia, whereas inactivating mutations are responsible for Hirschsprung disease. RET mutations have also been reported in fetuses with renal agenesis, based on analysis of a small series of samples. Objective and methods To characterise better the involvement of RET and GDNF in kidney development defects, a series of 105 fetuses with bilateral defects, including renal agenesis, severe hypodysplasia or multicystic dysplastic kidney, was studied. RET and GDNF coding sequences, evolutionary conserved non-coding regions (ECRs) in promoters, 3′UTRs, and RET intron 1 were analysed. Copy number variations at these loci were also investigated. Results The study identified: (1) a low frequency (<7%) of potential mutations in the RET coding sequence, with inheritance from the healthy father for four of them; (2) no GDNF mutation; (3) similar allele frequencies in patients and controls for most single nucleotide polymorphism variants, except for RET intron 1 variant rs2506012 that was significantly more frequent in affected fetuses than in controls (6% vs 2%, p=0.01); (4) distribution of the few rare RET variants unidentified in controls into the various 5′-ECRs; (5) absence of copy number variations. Conclusion These results suggest that genomic alteration of RET or GDNF is not a major mechanism leading to renal agenesis and other severe kidney development defects. Analysis of a larger series of patients will be necessary to validate the association of the RET intron 1 variant rs2506012 with renal development defects.


American Journal of Medical Genetics Part A | 2012

Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia

Lilia Kraoua; Hubert Journel; Philippe Bonnet; Jeanne Amiel; Nathalie Pouvreau; Clarisse Baumann; Alain Verloes; Hélène Cavé

Recently, germline mutations of NRAS have been shown to be associated with Noonan syndrome (NS), a relatively common developmental disorder characterized by short stature, congenital heart disease, and distinctive facial features. We report on the mutational analysis of NRAS in a cohort of 125 French patients with NS and no known mutation for PTPN11, KRAS, SOS1, MEK1, MEK2, RAF1, BRAF, and SHOC2. The c.179G>A (p.G60E) mutation was identified in two patients with typical NS, confirming that NRAS germline mutations are a rare cause of this syndrome. We also screened our cohort of 95 patients with juvenile myelomonocytic leukemia (JMML). Among 17 patients with NRAS‐mutated JMML, none had clinical features suggestive of NS. None of the 11 JMML patients for which germline DNA was available had a constitutional NRAS mutation.


Annals of the New York Academy of Sciences | 2010

Disruption of long-distance highly conserved noncoding elements in neurocristopathies

Jeanne Amiel; Sabina Benko; Christopher T. Gordon; Stanislas Lyonnet

One of the key discoveries of vertebrate genome sequencing projects has been the identification of highly conserved noncoding elements (CNEs). Some characteristics of CNEs include their high frequency in mammalian genomes, their potential regulatory role in gene expression, and their enrichment in gene deserts nearby master developmental genes. The abnormal development of neural crest cells (NCCs) leads to a broad spectrum of congenital malformation(s), termed neurocristopathies, and/or tumor predisposition. Here we review recent findings that disruptions of CNEs, within or at long distance from the coding sequences of key genes involved in NCC development, result in neurocristopathies via the alteration of tissue‐ or stage‐specific long‐distance regulation of gene expression. While most studies on human genetic disorders have focused on protein‐coding sequences, these examples suggest that investigation of genomic alterations of CNEs will provide a broader understanding of the molecular etiology of both rare and common human congenital malformations.


Journal of Medical Genetics | 2017

De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy

Stéphanie Guey; Lou Grangeon; F. Brunelle; Françoise Bergametti; Jeanne Amiel; Stanislas Lyonnet; Audrey Delaforge; Minh Arnould; Béatrice Desnous; Céline Bellesme; Dominique Hervé; Jan Claudius Schwitalla; Markus Kraemer; Elisabeth Tournier-Lasserve; Manoelle Kossorotoff

Background Moyamoya angiopathy (MMA) is characterised by a progressive stenosis of the terminal part of the internal carotid arteries and the development of abnormal collateral deep vessels. Its pathophysiology is unknown. MMA can be the sole manifestation of the disease (moyamoya disease) or be associated with various conditions (moyamoya syndrome) including some Mendelian diseases. We aimed to investigate the genetic basis of moyamoya using a whole exome sequencing (WES) approach conducted in sporadic cases without any overt symptom suggestive of a known Mendelian moyamoya syndrome. Methods A WES was performed in four unrelated early-onset moyamoya sporadic cases and their parents (trios). Exome data were analysed under dominant de novo, autosomal recessive and X-linked hypotheses. A panel of 17 additional sporadic cases with early-onset moyamoya was available for mutation recurrence analysis. Results We identified two germline de novo mutations in CBL in two out of the four trio probands, two girls presenting with an infancy-onset severe MMA. Both mutations were predicted to alter the ubiquitin ligase activity of the CBL protein that acts as a negative regulator of the RAS pathway. These two germline CBL mutations have previously been described in association with a developmental Noonan-like syndrome and susceptibility to juvenile myelomonocytic leukaemia (JMML). Notably, the two mutated girls never developed JMML and presented only subtle signs of RASopathy that did not lead to evoke this diagnosis during follow-up. Conclusions These data suggest that CBL gene screening should be considered in early-onset moyamoya, even in the absence of obvious signs of RASopathy.


European Journal of Human Genetics | 2018

CHARGE syndrome: a recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and minigene assays.

Marine Legendre; Montserrat Rodriguez Ballesteros; Massimiliano Rossi; Véronique Abadie; Jeanne Amiel; Nicole Revencu; Patricia Blanchet; Frédéric Brioude; Marie-Ange Delrue; Yassamine Doubaj; Christine Francannet; Muriel Holder-Espinasse; Pierre-Simon Jouk; Sophie Julia; Judith Melki; Sébastien Mur; Sophie Naudion; Jennifer Fabre-Teste; Tiffany Busa; Stephen Stamm; Stanislas Lyonnet; Tania Attié-Bitach; Alain Kitzis; Brigitte Gilbert-Dussardier; Frédéric Bilan

CHARGE syndrome is a rare genetic disorder mainly due to de novo and private truncating mutations of CHD7 gene. Here we report an intriguing hot spot of intronic mutations (c.5405-7Gu2009>u2009A, c.5405-13Gu2009>u2009A, c.5405-17Gu2009>u2009A and c.5405-18Cu2009>u2009A) located in CHD7 IVS25. Combining computational in silico analysis, experimental branch-point determination and in vitro minigene assays, our study explains this mutation hot spot by a particular genomic context, including the weakness of the IVS25 natural acceptor-site and an unconventional lariat sequence localized outside the common 40u2009bp upstream the acceptor splice site. For each of the mutations reported here, bioinformatic tools indicated a newly created 3’ splice site, of which the existence was confirmed using pSpliceExpress, an easy-to-use and reliable splicing reporter tool. Our study emphasizes the idea that combining these two complementary approaches could increase the efficiency of routine molecular diagnosis.


Archive | 2012

Cis-Regulatory Disruption at the SOX9 Locus as a Cause of Pierre Robin Sequence

Christopher T. Gordon; Sabina Benko; Jeanne Amiel; Stanislas Lyonnet

Mutations in the coding sequence of SOX9 cause the severe congenital skeletal disorder campomelic dysplasia (CD). A range of genomic lesions in the region upstream of the SOX9 coding sequence are also associated with CD, although often with milder phenotypic effects. Studies in humans and animal models suggest that these non-coding lesions disrupt SOX9 expression in specific tissues during embryonic development. Several lesions at the SOX9 locus, including translocations and microdeletions greater than 1 Mb upstream of the transcription start site, are associated with isolated Pierre Robin sequence (PRS), a craniofacial anomaly that is typically one part of the full-blown CD phenotype. In this chapter, we discuss how the lesions far upstream of SOX9 suggest a requirement for craniofacial-specific regulatory elements during SOX9 transcription in embryonic development and how the cis-ruption of these elements alone might result in isolated PRS, an endophenotype of CD.


The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017

Human Mutation in Endothelin A Receptor Provide an Insight into Structural Rearengement in GPCR

Yukiko Kurihara; Tomoko Doi; Taro Kitazawa; Risa Kotani; Yumiko Kawamura; Hiroki Higashiyama; Kazutoshi Tani; Christopher T. Gordon; Jeanne Amiel; Hiroki Kurihara


Archives De Pediatrie | 2010

Anomalies de dveloppement et prdisposition aux tumeurs de lenfant

Loïc de Pontual; Stanislas Lyonnet; Jeanne Amiel

Collaboration


Dive into the Jeanne Amiel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Loïc de Pontual

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Rémi Salomon

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

Sabina Benko

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Véronique Abadie

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge